期刊文献+

中国北方汉族人群尾加压素Ⅱ基因多态性与原发性高血压相关性研究 被引量:6

Role of UrotensinⅡ gene polymorphisms in susceptibility to the development of essential hypertension in a Northern Han Chinese population
下载PDF
导出
摘要 目的:研究高血压候选基因尾加压素Ⅱ(urotensinⅡ,UTS2)在中国北方汉族人群的分布,探讨UTS2基因Ser89Asn多态性与原发性高血压(essential hypertension,EH)的关系。方法:采集健康体检人群临床资料,分析体质量指数、血脂及血糖等临床指标,同时调查受检者吸烟和饮酒等生活习惯;TaqMan-MGB法分析UTS2基因Ser89Asn多态性在中国北方汉族人群(样本总数1 146例,其中EH病患者682例,血压正常的健康体检者464例)的分布及其与临床指标的相关性。结果:结果显示:UTS2的Ser89Asn基因型(P=0.037)和等位基因频率(P=0.039)在两组总体的差异具有统计学意义,性别亚组差异无统计学意义;调整其他影响因素后,Logistic回归模型分析显示,UTS2 EH总体和性别亚组的Ser89Asn基因多态性与EH无关。结论:在中国北方汉族人群中,未见UTS2基因Ser89Asn突变与原发性高血压相关。 Objective:The aim of the present study was to explore the potential association between the UrotensinⅡ(UTS2) gene polymorphisms and essential hypertension(EH) risk in the Northern Han Chinese population.Methods: This study included 682 hypertensive subjects and 464 healthy control subjects in the Northern Han Chinese.Genotyping was performed to identify the Ser89Asn polymorphisms of the UTS2 gene.Results: Significant associations were found in genotype frequencies(P=0.037) and in allele frequencies(P=0.039) between hypertensive and normotensiv groups(total).The data were subjected to logistic regression analysis after adjusting for confounding risk variables.No Significant associations were found between hypertensive and normotensiv groups(in both total and gender subgroup).Conclusion: Our research indicated that there was no significant association between Ser89Asn polymorphism of the UTS2 gene and hypertension in the Northern Han Chinese population.
出处 《心肺血管病杂志》 CAS 2013年第3期239-242,共4页 Journal of Cardiovascular and Pulmonary Diseases
基金 北京市自然科学基金资助项目(7133232 7120001) 国家自然科学基金资助项目(81270216) 国家高技术研究发展计划(863计划)资助项目(2008AA02Z441)
关键词 尾加压素Ⅱ基因 原发性高血压 单核苷酸多态性 UrotensinⅡ Essential hypertension Single-nucleotide polymorphism
  • 相关文献

参考文献17

二级参考文献56

  • 1孙晓健,侯晓菲,刘少荣,刘文波,张传焕.醛固酮合成酶基因-344T/C多态性与缬沙坦降压疗效相关性分析[J].中国综合临床,2005,21(11):961-962. 被引量:2
  • 2许丹,刘昌慧,郝亚容.尾加压素Ⅱ在心血管疾病中的研究进展[J].高血压杂志,2005,13(10):608-610. 被引量:2
  • 3[2]Takuya Watanabe,Toshiaki Suguro,Tomoko Kanome,et al.Human urotensin Ⅱ accelerates foam cell formation in human monocyte-derived macrophages[J].Hypertens,2005,46:738-744.
  • 4[3]Totsune K,Takahashi K,Arihara Z,et al.Increased plasma urotensin-Ⅱ levels in patients with diabetes mellitus[J].Clin Sei(Lond),2003,104:1-5.
  • 5[4]Rossowski WJ,Cheng BL,Taylor JE,et al.Human urotensinⅡinduced aorta ring contractions are mediated by protein kinase C,tyrosine kinasea and Rho kinase:inhibition by somatostatin receptor agonists[J].Eur J Pharmacol,2002,438:159-170.
  • 6[5]Watanabe T,Pakala R,Katagiri T,et al.Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell prolif eration[J].J Hypertens,2001,19:2191-2196.
  • 7[7]Done Onan,Luisa Pipolo,Eunice Yang,et al.Urotensin-Ⅱ promotes hypertrophy of cardiac myocytes via mitogen-activated protein Kinases[J].Molecular Endocrinology,2004,18:2344-2354.
  • 8[9]Bohm F,Penow J.Urotensin-Ⅱ evokes potent vasoconstriction in humans in vivol[J].Br J Pharmacol,2002,135:25-27.
  • 9Pehlivan Y, Onat AM, Cornez G, el al. Urotensin II in systemic sclerosis: a new peptide in pathogenesis [J]. Clin Rheumatol, 2011, 30 (6): 837 842.
  • 10Rodrigo R, Gonztilez J, Paoletto F. The role of oxidative stress in the pathophysiology of [J]. Hypertens Res, 2011, 34 (4): 431-440.

共引文献20

同被引文献49

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部